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Several reviews have so far pointed out on the relevant physiological and pharmacological
role exerted by neuroactive steroids in the central nervous system. In the present reviewwe
summarize observations indicating that synthesis and metabolism of neuroactive steroids
also occur in the peripheral nerves. Interestingly, peripheral nervous system is also a target
of their action. Indeed, as here reported neuroactive steroids are physiological regulators
of peripheral nerve functions and they may also represent interesting therapeutic tools for
different types of peripheral neuropathy.
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INTRODUCTION
Recent studies have shown that peripheral nerves synthesize and
metabolize neuroactive steroids. The term neuroactive steroid
refers to those steroids acting in the nervous system and includes
steroids produced by the nervous system (i.e., neurosteroids) and
hormonal steroids coming from classical steroidogenic tissues
(i.e., gonads and adrenal glands; Melcangi et al., 2008). More-
over, peripheral nerves express receptors for neuroactive steroids
and consequently represent a target for them. Indeed, neuroac-
tive steroids are involved in the regulation of different functions
of peripheral nerves, including Schwann cell proliferation and
myelination (Chan et al., 1998, 2000; Desarnaud et al., 1998, 2000;
Fex Svenningsen and Kanje, 1999; Lubischer and Bebinger, 1999;
Guennoun et al., 2001; Mercier et al., 2001; Azcoitia et al., 2003;
Rodriguez-Waitkus et al., 2003; Tanzer and Jones, 2004; Melcangi
et al., 2005; Magnaghi et al., 2006, 2007).
Peripheral neuropathy is one of the most common disorders
with a prevalence of about 2.4% that rises with aging to 8% in
the general population (England and Asbury, 2004). Peripheral
neuropathy may be inherited, such as those referred to Charcot–
Marie–Tooth (CMT) disease including demyelinating and axonal
variants, or acquired, like for instance those occurring during
aging process, after physical injury, in systemic or metabolic dis-
orders (e.g., diabetes mellitus, vitamin deﬁciencies, alcoholism,
kidney failure, cancer, etc.), in infections and autoimmune disor-
ders (e.g.,AIDS,hepatitis,Guillain–Barré syndrome,Lymedisease,
rheumatoid arthritis, leprosy, sarcoidosis, syphilis, systemic lupus
erythematosus, etc.), after exposure to toxic compounds and dur-
ing drug treatment (e.g., chemotherapeutic, antiretroviral, anti-
tuberculosis medications, antimicrobial drugs, lithium, etc.). Cur-
rently, therapeutic arsenal for these peripheral neuropathies is
very limited. Therefore, the ﬁnding that neuroactive steroids act
as protective agents in different experimental models of periph-
eral neuropathy is highly promising (Leonelli et al., 2006; Mel-
cangi and Garcia-Segura, 2006, 2010; Roglio et al., 2008b; Schu-
macher et al., 2008). At present, corticosteroids are the only
steroids used for clinical management of peripheral neuropathy,
due to their anti-inﬂammatory actions. However, the design of
a randomized controlled trial for the treatment of mild idio-
pathic carpal tunnel syndrome (CTS) with local injection of
17 alpha-hydroxyprogesterone caproate, a synthetic derivative of
progesterone (PROG), has been recently reported (Milani et al.,
2010).
We will here review the state of the art on the synthesis,
actions, and therapeutic implications of neuroactive steroids in
the peripheral nervous system (PNS).
SYNTHESIS OF NEUROACTIVE STEROIDS OCCURS IN THE
PERIPHERAL NERVES
Peripheral nerves are a source of neuroactive steroids (Mellon and
Deschepper, 1993; Schumacher et al., 2003; Melcangi et al., 2008;
Pelletier, 2010). The ﬁrst step of steroidogenesis is the transport
of cholesterol from intracellular stores to the inner mitochondrial
membrane,where cytochrome P450 side chain cleavage (P450scc),
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the enzyme that converts cholesterol to pregnenolone, is located.
This transport is facilitated by translocator protein-18kDa (TSPO)
and steroidogenic acute regulatory protein (StAR), two mole-
cules that, together with P450scc, are expressed by Schwann cells
(Benmessahel et al., 2004; Papadopoulos et al., 2006).
Moreover, Schwann cells, as well as dorsal root ganglia
(DRG), also express other steroidogenic enzymes such as 3α-
hydroxysteroid dehydrogenase (i.e., the enzyme converting PREG
into PROG; Koenig et al., 1995; Guennoun et al., 1997; Chan et al.,
2000; Schumacher et al., 2001; Coirini et al., 2003; Rodriguez-
Waitkus et al., 2003; Schaeffer et al., 2010), 5α-reductase (5α-
R), converting PROG and testosterone (T) into dihydroproges-
terone (DHP) and dihydrotestosterone (DHT) respectively, and
3α-hydroxysteroid dehydrogenase, converting DHP and DHT into
tetrahydroprogesterone (THP) and 5α-androstane-3α, 17β-diol
(3α-diol) respectively (Melcangi et al., 1990, 2001a; Yokoi et al.,
1998; Schaeffer et al., 2010). Synthesis of neuroactive steroids in
peripheral nerves has been also conﬁrmed by the assessment of
their levels. For instance, using liquid chromatography tandem
mass spectrometry analysis, levels of PREG, PROG, and its deriva-
tives (i.e., DHP, THP and isopregnanolone), dehydroepiandros-
terone (DHEA), T, and its derivatives (i.e., DHT and 3α-diol)
have been determined in the sciatic nerve of male and female rats
(Caruso et al., 2008a,b, 2010; Pesaresi et al., 2010b). These studies
have shown that local levels of neuroactive steroids in the periph-
eral nerve do not directly reﬂect plasma levels. In addition, these
studies have revealed that the PNS adapts its local levels of neu-
roactive steroids in response to gonadectomy with sex speciﬁcity
and depending on the duration of the peripheral modiﬁcations
(Caruso et al., 2010).
PHYSIOLOGICAL CONTROL BY NEUROACTIVE STEROIDS ON
PERIPHERAL NERVES
PERIPHERAL NERVES AS TARGETS OF NEUROACTIVE STEROIDS
Peripheral nerves and Schwann cells not only synthesize and
metabolize neuroactive steroids,but are also targets for thesemole-
cules. Classical intracellular steroid receptors, such as PROG (PR),
estrogen, glucocorticoid, and mineralocorticoid receptors, have
been detected in rat sciatic nerve and in Schwann cells (Jung-
Testas et al., 1996; Melcangi et al., 2001b; Groyer et al., 2006).
Also, androgen receptor (AR) expression has been demonstrated
in the endoneurial compartment of rat sciatic nerve (Magnaghi
et al., 1999; Jordan et al., 2002). Through the activation of these
classical steroid receptors, neuroactive steroids such as PROG,
DHP, T, DHT, DHEA, estrogens, and corticosteroids, affect the
development and function of the PNS.
In addition, in the central nervous system, neuroactive steroids
such as 3alpha-hydroxy-derivatives of dihydroprogesterone, dihy-
drotestosterone, and deoxycorticosterone are known to bind to
neurotransmitter receptor channels and to modulate their activity
(Lambert et al., 2003; Belelli and Lambert, 2005; Zheng, 2009).
This mechanism of action also operates in the PNS, since neu-
rotransmitter receptors modulated by neuroactive steroids, such
as GABA-A (i.e., α2, α3, β1, β2, and β3 subunits) and GABA-B
(i.e., GABA-B1 and GABA-B2) receptors, have been identiﬁed in
peripheral nerves and Schwann cells (Melcangi et al., 1999; Mag-
naghi et al., 2004a). Moreover, rat sural nerve expresses NMDA
receptor 1 subunit, glutamate receptor 1 (GluR1), AMPA subunit,
and GluR 5, 6, 7 kainate subunits (Coggeshall and Carlton, 1998;
Verkhratsky and Steinhauser, 2000). Schwann cells of mammalian
peripheral vestibular system express GluR 2, 3, 4 (Dememes et al.,
1995; Verkhratsky and Steinhauser, 2000). Finally, the presence
of sigma 1 receptor (i.e., an atypical neuro-modulatory receptor)
in Schwann cells of rat sciatic nerve has been conﬁrmed (Palacios
et al., 2004). Therefore, neuroactive steroids may also regulate PNS
physiology through the modulation of the activity of neurotrans-
mitter receptors and by non-classical steroid receptors, such as the
sigma 1 receptor.
EFFECTS, MECHANISMS OF ACTION, AND INFLUENCE OF SEX
Oneof best characterized actions of neuroactive steroids inperiph-
eral nerves is the regulation of the myelination program. Classical
and non-classical steroid receptors mediate physiological actions
of neuroactive steroids on the proliferation of Schwann cells and
on their expression of myelin proteins and of transcription fac-
tors involved in the regulation of myelination (Figure 1). Indeed,
PROG and its derivatives are able to modulate the expression of
myelin proteins of the PNS, such as glycoprotein zero (P0) and the
peripheral myelin protein 22 (PMP22). Namely, the expression of
P0 in sciatic nerve of adult male rats, as well as that in rat Schwann
cell culture, was increased by the treatment with PROG, DHP, or
THP, while in case of PMP22, only THP was effective (Melcangi
et al., 1999, 2005). Similar effects are also exerted by derivatives of
T.Thus,orchidectomy in adultmale rat decreased the expressionof
P0 and PMP22 in the sciatic nerve (Magnaghi et al., 1999, 2004b).
The subsequent treatment with DHT or 3α-diol (i.e., two deriva-
tives of T) restored the levels of P0, while in case of PMP22 only
3α-diol was effective (Magnaghi et al., 1999, 2004b). A very sim-
ilar pattern of effects was also evident in cultures of rat Schwann
cells (Melcangi et al., 2005). The mechanism involved in these
effects was different depending on the myelin protein considered.
Thus, observations performed with receptor agonists or antag-
onists suggest that the expression of P0 is under the control of
classical intracellular receptors, such as PR andAR,while a role for
non-classical mechanisms, like the modulation of GABA-A recep-
tor,may be hypothesized in case of PMP22 (Melcangi et al., 2005).
Activation of a classical steroid receptor, such as PR, clearly sug-
gests that the effect of PROG derivatives on P0 expression is due
to a classical steroid genomic effect. This hypothesis is supported
by the ﬁnding that putative progesterone responsive elements are
present on P0 gene (Magnaghi et al., 1999) and that a coactivator,
such as steroid receptor coactivator-1 (SRC-1), participates in the
regulation of P0 gene expression by DHP. Indeed, the effect of this
neuroactive steroid on P0 expression in an immortalized cell line
of Schwann cell (i.e., MSC80 cells) stably transfected to over- or
down-express SRC-1 was increased or completely lost, respectively
(Cavarretta et al., 2004). A role for AR in controlling expression
of P0 may be also hypothesized. Indeed, in vivo treatment with an
AR antagonist, such as ﬂutamide, decreased the synthesis of P0 in
rat sciatic nerve (Magnaghi et al., 2004b). Interestingly, inhibition
of AR inﬂuenced P0 synthesis in adult age only. This age-linked
effect is different from what we have observed after the in vivo
treatment with mifepristone, where PR antagonist was only able
to decrease the synthesis of P0 at postnatal day 20 (Melcangi et al.,
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FIGURE 1 | Physiological effects of neuroactive steroids in peripheral
nerves.
2003b). A possible hypothesis could be that PROG derivatives
may be necessary for inducing P0 synthesis during the ﬁrst steps
of the myelination process, while the subsequent intervention of
T derivatives will participate in the maintenance of this process.
At variance towhat observed onP0, expression of PMP22 seems
to be under the control of GABA-A receptor. As we observed in
Schwann cell cultures, treatment with antagonist (i.e., bicuculline)
or agonist (i.e.,muscimol) of GABA-A receptor abolished ormim-
icked respectively the stimulatory effect exerted byTHPonPMP22
(Melcangi et al., 2005).
Expression of P0 and PMP22 is also affected in a sex-dependent
manner. Thus, observations obtained in culture of rat Schwann
cells have indicated that PROG or DHP treatment induced a stim-
ulatory effect on P0 mRNA levels only in male, while THP was
only effective in female cells. Similarly, the expression of PMP22
was stimulated by PROG in cultures from males and by THP in
cultures from females (Magnaghi et al., 2006).
Neuroactive steroids regulate myelination program by affect-
ing also the expression of transcription factors (Figure 1). Data
obtained in culture of rat Schwann cells (Guennoun et al., 2001;
Mercier et al., 2001) have indicated that PROG stimulates the gene
expression of Krox-20, Krox-24, Egr-3, and FosB. Moreover, the
expression of Krox-20 was also stimulated by DHP and THP,
while that of another transcription factor, such as Sox-10, was
only stimulated by DHP (Magnaghi et al., 2007).
P0 and PMP22 play an important role for the maintenance of
the multilamellar structure of PNS myelin (D’Urso et al., 1990).
Therefore, in agreement with the effect exerted on the proteins
of peripheral myelin, PROG is also able to stimulate the synthesis
of myelin membranes (Figure 1). For instance, PROG accelerates
the time of initiation and enhances the rate of myelin synthesis in
Schwann cells co-cultured with DRG neurons (Chan et al., 1998,
2000).
Moreover, also the axonal compartment of PNSneurons is a tar-
get for the action of neuroactive steroids. Thus, PROG affects the
expression of neuronal genes involved in the myelination process
by Schwann cells. For instance, in co-culture of Schwann cells and
DRGneurons two genes, like a small Ras-likeGTP-binding protein
(Rap 1b) and phosphoribosyl diphosphate synthase-associated
protein, which are induced in co-cultures during myelin synthe-
sis, were also induced by PROG treatment (Chan et al., 2000;
Rodriguez-Waitkus et al., 2003). Finally, the blockade of PR by
mifepristone during development resulted in axonal impairment
in the sciatic nerve of male rats (Melcangi et al., 2003b).
Neuroactive steroids are also able to affect Schwann cell prolif-
eration (Figure 1). For instance, a stimulatory effect of PROG has
been detected in vitro (Fex Svenningsen and Kanje, 1999; Barto-
lami et al., 2003). Interestingly, also this effect of PROG seems to
be dependent on the sex of the animals. Indeed, PROG increased
Schwann cell proliferation in cultures of segments of rat sciatic
nerve from females, but was ineffective in cultures from males (Fex
Svenningsen and Kanje, 1999). Androgens also affect Schwann
cell proliferation. For instance, the number of terminal Schwann
cells unsheathing the synaptic junction between motor nerve end-
ings and muscles decreased after castration and this effect was
counteracted by T replacement (Lubischer and Bebinger, 1999).
Steroid coactivators,which as previouslymentioned participate
in the effects exerted by neuroactive steroids on myelin proteins,
are also able to affect cell proliferation. For instance, cell prolif-
eration in an immortalized line of Schwann cells (i.e., MSC80
cells) overexpressing SRC-1 was slower than in cells in which
the coactivator expression was down regulated (Melcangi et al.,
2005). In contrast, overexpression of another coactivator, such as
steroid receptor RNA activator (SRA), induced an increase in the
proliferation of MSC80 cells (Melcangi et al., 2005).
Finally, metabolites of PROG, such as THP, acting on GABA-A
receptors are also able to inﬂuence GABA and glutamate pathways
in Schwann cells (Figure 1). Thus, this neuroactive steroid stim-
ulates GABA synthesis by increasing the levels of glutamic acid
decarboxylase of 67 kDa (Magnaghi et al., 2010) and the activity
of excitatory amino acid carrier 1 and therefore, glutamate uptake
(Perego et al., 2011).
THE LEVELS OF NEUROACTIVE STEROIDS IN PERIPHERAL
NERVES ARE AFFECTED BY PATHOLOGICAL EVENTS
As demonstrated in several experimental models, the levels of
neuroactive steroids present in peripheral nerves are affected by
traumatic injury and pathologies. Namely, in the experimental
model of crush injury the levels of PREG, DHP, and THP present
in the distal portion of injured sciatic nerve were lowered (Roglio
et al., 2008a). The drop of DHP was not explained by a decrease in
the levels of its ﬁrst substrate (i.e., PROG) that were unchanged,
but by a decrease in the expression of the enzyme 5α-R (i.e.,
enzyme converting PROG into DHP; Roglio et al., 2008a).
Changes in the levels of neuroactive steroids have been also
reported in an experimental model of Charcot–Marie–Tooth type
1 (CMT1A;Caruso et al.,2008b)orof diabetic neuropathy (Caruso
et al., 2008a; Pesaresi et al., 2010b). Interestingly, in these experi-
mental models the levels of neuroactive steroids were affected in
a sex-dimorphic way by the pathology. For instance, as demon-
strated in the sciatic nerve of male and female PMP22 transgenic
rats (i.e., an experimental model of CMT1A) the levels of isopreg-
nanolone and of 3α-diol, which are exclusively detectable in sciatic
nerve of female and male rats respectively, were strongly decreased
(Caruso et al., 2008b). In sciatic nerve of streptozotocin (STZ)-
treated animals (i.e., an experimental model of diabetes inducing
peripheral neuropathy), the levels of PREG, T, DHT, and 3α-diol
were signiﬁcantly decreased in males but not in females, while
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PROG, THP, and isopregnanolone were decreased only in females
(Pesaresi et al., 2010b).
NEUROACTIVE STEROIDS AS PROTECTIVE AGENTS IN
PERIPHERAL NERVOUS SYSTEM
Neuroactive steroids are not only protective agents in the central
nervous system as extensively demonstrated in several experimen-
tal models (Melcangi et al., 2000a; Lapchak and Araujo, 2001;
McCullough and Hurn, 2003; Ciriza et al., 2004, 2006; Grifﬁn
et al., 2004; Melcangi and Mensah-Nyagan, 2006; Aguado-Llera
et al., 2007; Schumacher et al., 2007; Pesaresi et al., 2010a), but
they are also effective on peripheral neuropathies (Figure 2).
AGING
Aging induces important biochemical (e.g., a decrease in the syn-
thesis of P0 and PMP22) and morphological changes in peripheral
nerves, such as atrophy of the large myelinated ﬁbers, myelin
sheaths increase in thickness and show various irregularities (i.e.,
myelin ballooning, splitting, infolding, reduplication, and remyeli-
nation; Azcoitia et al., 2003; Melcangi et al., 2003a). Neuroactive
steroids, such as PROG or its derivatives, are able to stimulate the
low expression of P0 and PMP22 in the sciatic nerve of aged rats
(Melcangi et al., 1998,2000c,2003a).Moreover, they have also clear
beneﬁcial effects on the number and shape of myelinated ﬁbers as
well as on the frequency of myelin abnormalities (Azcoitia et al.,
2003; Melcangi et al., 2003a).
All these effects seem to be a peculiarity of PROG and its deriv-
atives, because neither T nor DHT or 3α-diol were able to inﬂu-
ence the morphological parameters analyzed in these experiments
(Azcoitia et al., 2003; Melcangi et al., 2003a).
PHYSICAL INJURY
Protective and regenerative effects of neuroactive steroids have
been well characterized in experimental models of degeneration
occurring after physical injury of peripheral nerves. For instance,
(1) PROG or DHP, increase gene expression of P0 after nerve
transection (Melcangi et al., 2000b); (2) PREG and PROG coun-
teract the decrease of the amounts of myelin membranes induced
by a cryolesion in the sciatic nerve of the mouse (Koenig et al.,
1995); (3) In guided regeneration of facial nerve of rabbit, PROG
induces an increase in the number of Schwann cell nuclei, of non-
myelinated and myelinated nerve ﬁbers (with increase also in their
FIGURE 2 | Pathological targets of neuroactive steroids in the
peripheral nervous system.
diameters), as well as in the g-ratio of myelinated nerve ﬁbers
(Chavez-Delgado et al., 2005); and (4) In crush injurymodel,DHP
and/or P counteract biochemical alterations (i.e., myelin proteins
and Na+,K+-ATPase pump) and stimulate reelin gene expres-
sion. These two neuroactive steroids also counteract nociception
impairment, and DHP treatment signiﬁcantly decreases the up-
regulation of myelinated ﬁbers’ density occurring in crushed
nerves (Roglio et al., 2008a).
Moreover, promising results have been also obtained with other
neuroactive steroids. For instance,T and its derivative,DHT, accel-
erate regeneration, and functional recovery of injured nerves (Yu,
1982; Vita et al., 1983; Jones et al., 2001; Tanzer and Jones, 2004;
Huppenbauer et al., 2005). DHEA is protective after rat sciatic
nerve transection, reducing the extent of denervation atrophy and
inducing an earlier onset of axonal regeneration (Ayhan et al.,
2003). DHEA also promotes a faster return to normal values of sci-
atic function index and increases the number of myelinated ﬁbers
and of ﬁber diameters after nerve crush injury in rats (Gudemez
et al., 2002). Similar results have been obtained after crush injury
in mice, using 17β-estradiol (Islamov et al., 2002).
CHEMOTHERAPY-INDUCED PERIPHERAL NEUROTOXICITY
Effects of neuroactive steroids have been also evaluated in an
experimental model of chemotherapy-induced peripheral neu-
rotoxicity, such as those due to docetaxel (i.e., a semisynthetic
taxane widely employed as antineoplastic agent for the treatment
of breast, ovarian, and non-small cell lung cancer; Roglio et al.,
2009). We demonstrated that treatment with DHP or P counter-
acted docetaxel-inducedneuropathy,preventing nerve conduction
velocity (NCV) and thermal threshold changes, and degeneration
of skin nerves in the footpad. Neuroactive steroids also counter-
acted the changes in gene expression of several myelin proteins,
such as P0, PMP22, myelin, and lymphocyte-associated protein
and myelin basic protein (MBP) induced by docetaxel in sciatic
nerve. Most nerve abnormalities observed during the treatment
with docetaxel spontaneously recovered after drug withdrawal,
similarly to what occurs in patients. However, results of midterm
follow-up experiments indicate that animals treated with DHP or
P show a faster recovery (Roglio et al., 2009).
Neuropathic pain is another important consequence of periph-
eral nerve damage. Indeed, neuroactive steroids exert a beneﬁcial
effect also on this component. For instance, DHP or THP treat-
ment suppresses neuropathic symptoms (allodynia/hyperalgesia)
evoked by antineoplastic drugs such as vincristine (Meyer et al.,
2010) or oxaliplatin (Meyer et al., 2011).
DIABETIC NEUROPATHY
Another experimental model in which protective effects of neu-
roactive steroids have been ascertained is diabetic neuropathy.
Thus, in STZ-treated rats, PROG or its derivatives improve sci-
atic NCV, myelin protein mRNA levels (i.e., P0 and PMP22), Na+,
K+-ATPase activity, thermal threshold, skin innervation density
(Leonelli et al., 2007) and counteract the increase in the number of
ﬁbers with myelin infoldings (Veiga et al., 2006). Androgens, such
asTor its derivatives exert similar effects (Roglio et al., 2007),while
DHEA prevents not only neuronal but also vascular dysfunction
in the sciatic nerve of STZ-rats (Yorek et al., 2002).
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INFLUENCE OF HORMONAL ENVIRONMENT
As recently demonstrated, endogenous glucocorticoids exert a role
in myelination after sciatic nerve injury. For instance, crush injury
performed in adrenalectomized rats affects myelination processes
in term of MBP expression and morphological parameters of
myelin sheaths (Morisaki et al., 2010). Thus, adrenalectomized
animals showed reduced MBP mRNA and protein levels and
decreased myelin thickness in comparison to sham-operated ani-
mals. These alterations were prevented by low-dose corticosterone
replacement.
Recent results have shown that gonadal steroid hormonal envi-
ronment also inﬂuences diabetic neuropathy. Interestingly, this
effect is sex-dimorphic. Thus, ovariectomy, but not orchidectomy,
signiﬁcantly counteract STZ-induced alterations on NCV, Na+,
K+-ATPase activity, and expression of myelin proteins, such as P0
and PMP22 (Pesaresi et al., 2011). The effect of ovariectomy is
associated with an increase in the levels of neuroactive steroids
(e.g., DHEA, T, and DHT) in the sciatic nerve of diabetic rats
(Pesaresi et al., 2011).
These observations, together with the ﬁnding that peripheral
neuropathies show sex differences in their incidence, sympto-
matology, and nerodegenerative outcome (Melcangi and Garcia-
Segura, 2010) may have strong implications for the development
of new sex-oriented therapies based on the use of neuroactive
steroids.
NEUROPROTECTIVE EFFECTS BY STEROID RECEPTOR
MODULATORS
An alternative to the use of P, DHP, and THP may be the use of
molecules that target PR and/orGABA-A receptor (Melcangi et al.,
2005). Indeed, it has been demonstrated that the treatment with a
PRantagonist (i.e.,onapristone)was able to reduce the overexpres-
sionof PMP22and to improveCMTphenotype in an experimental
model of CMT1A (i.e., PMP22-transgenic rats; Sereda et al., 2003;
Meyer zu Horste et al., 2007). This opens the possibility of using
selective PR modulators, perhaps in combination with GABA-A
ligands, for the treatment of peripheral neuropathy. Selective estro-
gen receptor modulators may also offer a potential therapeutic
interest since the selective estrogen receptor modulator LY117018
has been shown to enhance functional recovery after injury of the
sciatic nerve (McMurray et al., 2003).
IN SITU INDUCTION OF NEUROACTIVE STEROIDS AS
THERAPEUTIC TOOLS
Another alternative for a therapeutic strategy with neuroactive
steroids themselves, or with speciﬁc synthetic ligands of their
receptors,might be the use of pharmacological agents that increase
the synthesis of endogenous neuroactive steroids within the ner-
vous system. For instance, this is possible with ligands of TSPO,
which promoting the translocation of cholesterol to the inner
mitochondrial membrane increase the synthesis of neuroactive
steroids. As reported, a TSPO ligand like SSR180575 was able to
increase the survival of facial nerve motoneurons after axotomy
and the regeneration of peripheral nerves (Ferzaz et al., 2002).
Another TSPO ligand, such as Ro5-4864, exerted a beneﬁcial effect
on morphological parameters of the sciatic nerve of aged male
rats, signiﬁcantly increasing the total number of myelinated ﬁbers
and decreasing the percentage of ﬁbers with myelin decompaction
(Leonelli et al., 2005). Moreover, Ro5-4864 is effective on STZ-
induced diabetic neuropathy and signiﬁcantly stimulates the low
levels of PREG, PROG, and DHT observed in the sciatic nerves of
diabetic rats (Giatti et al., 2009). In agreement with the protective
actions of these neuroactive steroids, activation of TSPO coun-
teracted the impairment of NCV and thermal threshold, restored
skin innervation density and P0 gene expression, and improved
Na+, K+-ATPase activity (Giatti et al., 2009).
Etifoxine (i.e., a TSPO ligand used for the treatment of anxiety
disorders) has been demonstrated to activate neuroactive steroid
synthesis (Verleye et al., 2005). In experimental models of periph-
eral nerve lesion, etifoxine treatment improved peripheral nerve
regeneration and functional recovery, increasing axonal growth,
causing a marked reduction in the number of macrophages
and improving recovery of locomotion, motor coordination and
sensory functions (Girard et al., 2008).
Finally, also liver X receptors (LXRs) might be an interesting
therapeutic target (Cermenati et al., 2010). LXRs are ligand acti-
vated transcription factors that belong to the nuclear receptor
superfamily that serving as cholesterol sensors prevent excessive
intracellular accumulation of cholesterol.
As recently demonstrated, sciatic nerve expresses functional
LRXα and β isoforms. Treatment with a synthetic ligand of this
receptors (i.e., GW3965) resulted in an increase of neurosteroido-
genesis in the sciatic levels of diabetic animals. Thus, an increase
of the levels of PREG, PROG, DHP, and 3α-diol and of molecules
and enzymes involved in their synthesis, such as StAR, P450scc,
and 5α-R, as well as of classical LXR targets involved in cho-
lesterol efﬂux, such as ABCA1 and ABCG1 was observed. These
changes in neurosteroidogenesis machinery were associated with
neuroprotective effects on thermal nociceptive activity, NCV and
Na+, K+-ATPase activity (Cermenati et al., 2010). Interestingly,
recent results have indicated that LXRs may also affect peripheral
myelination opening new perspectives in the treatment of periph-
eral neuropathy. Indeed, knock-out of LXR in mice results in an
alteration of the phenotype of myelin sheaths surrounding axons
(i.e., thinner myelin sheaths), without affecting the diameters and
number of axons (Makoukji et al., 2011).
CONCLUDING REMARKS
Observations here reviewed indicate that the PNS is a target for
the effects of neuroactive steroids. In addition,neuroactive steroids
themselves or pharmacological approaches acting on their recep-
tors or their synthesis might represent potential therapeutic tools
for different forms of peripheral neuropathies. This is extremely
interesting because in many situations there are no effective treat-
ments that can stop or reverse peripheral nerve damage. Thus, a
sustained research and development effort on this experimental
ﬁeld might permit in a close future a promising translation to
clinical research.
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